Pentasa belongs to a group of medications called aminosalicylates. It is thought that the drug works by inhibiting the production of inflammatory chemicals in the lining of the
colon. Pentasa decreases the production of prostaglandins and leukotrienes, chemicals that lead to the inflammation caused by
ulcerative colitis.
Pentasa capsules are controlled-release, meaning they dissolve slowly over time. This allows the medication to be released throughout the gastrointestinal tract.
Pentasa has not been approved for the treatment of ulcerative colitis in children. Be sure to talk with your healthcare provider about the risks and benefits of using the drug in children.
On occasion, your healthcare provider may recommend Pentasa for treating something other than ulcerative colitis. This is called an "
off-label" use. At this time, using Pentasa to treat
Crohn's disease is considered an off-label use for the drug.